Immunovia AB

Immunovia AB
About Us
Contacts
Change country

Follow us:
Share:
Subscribe:

About Us

Immunovia AB is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer. Our first product, IMMray™ PanCan-d is the only blood test currently available specifically for the early detection of pancreatic cancer. The test has unmatched clinical performance. Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups globally to make this test available to all high-risk pancreatic cancer groups. The USA, the first market in which IMMray™ PanCan-d is commercially available, is the world’s largest market for the detection of pancreatic cancer with an estimated value of more than USD 4 billion annually. Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

Contacts

Immunovia AB
Medicon Village Scheelevägen 8 SE-223 63 Lund
+46 46 275 60 00
http://www.immunovia.com
info@immunovia.com

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Immunovia Publishes Report for the Second Quarter 2021

Thu, Aug 19, 2021 16:00 CET

LUND (SWEDEN) – Immunovia AB (publ) (“Immunovia”) has today published its report for the second quarter 2021. It is available on Immunovia’s website. Patrik Dahlen, CEO: “We started the quarter by applying for a Massachusetts State License and CLIA Certification of the Immunovia, Inc. laboratory in Marlborough. After the period we received final approval to start patient testing with IMMray™ PanCan-d in the US. We are now very pleased to have received the final approval of our laboratory and that we now can launch the IMMray™ PanCan-

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Contacts

Immunovia Publishes Report for the Second Quarter 2021

Subscribe

Media